Mediar Therapeutics: Global Licensing Agreement With Eli Lilly to Advance Mtx-463 Into a Phase 2 Clinical Trial for Idiopathic Pulmonary Fibrosis
Mediar Therapeutics:與禮來公司達成全球貨幣授權協議,以推進Mtx-463進入特發性肺纖維化的第二階段臨牀試驗
Mediar Therapeutics: Global Licensing Agreement With Eli Lilly to Advance Mtx-463 Into a Phase 2 Clinical Trial for Idiopathic Pulmonary Fibrosis
Mediar Therapeutics:與禮來公司達成全球貨幣授權協議,以推進Mtx-463進入特發性肺纖維化的第二階段臨牀試驗
使用瀏覽器的分享功能,分享給你的好友吧